Investors

Press Releases

All Releases

View Summary Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps
Sep 30, 2014
PDF 16.2 KB Add to Briefcase
View Summary Regeneron Announces EYLEA® (aflibercept) Injection Approved for the Treatment of Patients with Myopic Choroidal Neovascularization (CNV) in Japan
Sep 22, 2014
PDF 14.6 KB Add to Briefcase
View Summary EYLEA® (aflibercept) Injection Receives FDA Breakthrough Therapy Designation for Diabetic Retinopathy in Patients with Diabetic Macular Edema
Sep 16, 2014
PDF 20.3 KB Add to Briefcase
View Summary Regeneron Announces Submission of Application for EYLEA® (aflibercept) Injection in Japan for Macular Edema Following Branch Retinal Vein Occlusion
Sep 4, 2014
PDF 17.6 KB Add to Briefcase
View Summary Regeneron and Sanofi Announce Presentation of Detailed Positive Results from Four Pivotal Alirocumab Trials at ESC Congress 2014
Aug 31, 2014
PDF 22.8 KB Add to Briefcase
View Summary Regeneron and Sanofi to Present Results from Four Phase 3 Alirocumab Trials in Hot Line Session at ESC Congress 2014
Aug 25, 2014
PDF 20.1 KB Add to Briefcase
View Summary Regeneron Announces Upcoming 2014 Investor Conference Presentations
Aug 19, 2014
PDF 8.7 KB Add to Briefcase
View Summary EYLEA® (aflibercept) Injection Receives EU Approval for the Treatment of Diabetic Macular Edema (DME)
Aug 11, 2014
PDF 17.6 KB Add to Briefcase
View Summary Regeneron Reports Second Quarter 2014 Financial and Operating Results
Aug 5, 2014
PDF 38.6 KB Add to Briefcase
View Summary Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission
Jul 30, 2014
PDF 15.9 KB Add to Briefcase
View Summary Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia
Jul 30, 2014
PDF 19.5 KB Add to Briefcase
View Summary EYLEA® (aflibercept) Injection Receives FDA Approval for the Treatment of Diabetic Macular Edema (DME)
Jul 29, 2014
PDF 22.3 KB Add to Briefcase
View Summary Regeneron to Report Second Quarter 2014 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2014
Jul 18, 2014
PDF 8.5 KB Add to Briefcase
View Summary Two-Year Results From Phase 3 VIVID-DME Trial of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema Show Sustained Improvement in Vision
Jul 18, 2014
PDF 21.2 KB Add to Briefcase
View Summary Regeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis
Jul 9, 2014
PDF 20.1 KB Add to Briefcase
View Summary EYLEA® (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment due to Diabetic Macular Edema in the European Union
Jun 27, 2014
PDF 21.2 KB Add to Briefcase
View Summary Sanofi and Regeneron Announce New, Detailed Data from Positive Sarilumab Phase 3 Rheumatoid Arthritis Trial at EULAR
Jun 12, 2014
PDF 18.2 KB Add to Briefcase
View Summary EYLEA® (aflibercept) Injection Submitted for EU Marketing Authorization for the Treatment of Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)
Jun 11, 2014
PDF 18.5 KB Add to Briefcase
View Summary Regeneron Announces Winners of the 2014 Regeneron Prize for Creative Innovation
Jun 2, 2014
PDF 10.2 KB Add to Briefcase
View Summary Regeneron Announces Update to Upcoming 2014 Investor Conference Presentations
May 30, 2014
PDF 8.7 KB Add to Briefcase
Showing 1-20 of 238 Page: 1 2 3 4 5 ... 12  Next 20
Add to Briefcase = add release to Briefcase


Close
Form content here please :)